Information on Mounjaro Pen
We are aware of recent media reports regarding obesity drugs in relation to the central NHS press release. As is commonly the case a national press release occurs prior to services being set up. Please do NOT contact the practice enquiring about GLP1a drugs e.g. Tirzepatide (Mounjaro) for obesity / weight management. You will be advised to wait on further regional developments.
Cheshire and Merseyside ICB are scoping the commissioning of local obesity clinics to manage this process as a means of avoiding a collapse in General Practice access. As such the practice will only be prescribing these drugs for diabetic patients who meet the criteria.
Have a body mass index (BMI) of 40 kg/m² or more (or 37.5 kg/m² for people from minority ethnic family backgrounds)
and
Have at least four of the following long-term conditions:
1. Type 2 diabetes
2. Hypertension (high blood pressure)
3. Dyslipidaemia
4. Established cardiovascular disease
5. Obstructive sleep apnoea
For more information please click button below.